kabutan

Daito Pharmaceutical Co.,Ltd.(4577) Summary

4577
TSE Prime
Daito Pharmaceutical Co.,Ltd.
1,333
JPY
+10
(+0.76%)
Jan 29, 3:30 pm JST
8.71
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
17.0
PBR
0.75
Yield
3.00%
Margin Trading Ratio
57.10
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
1,315 JPY 8.58 USD
Previous Close Jan 28
1,323 JPY 8.66 USD
High Jan 29, 1:33 pm
1,334 JPY 8.71 USD
Low Jan 29, 9:22 am
1,306 JPY 8.53 USD
Volume
211,700
Trading Value
0.28B JPY 1.84M USD
VWAP
1329.55 JPY 8.69 USD
Minimum Trading Value
133,300 JPY 871 USD
Market Cap
0.04T JPY 0.26B USD
Number of Trades
345
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
233
1-Year High Jul 14, 2025
1,532
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 35,400 44,300 1.25
Jan 16, 2026 26,000 42,500 1.63
Jan 9, 2026 22,800 48,000 2.11
Dec 26, 2025 27,200 45,900 1.69
Dec 19, 2025 20,900 43,800 2.10
Company Profile
Daito Pharmaceutical Co., Ltd. specializes in the manufacturing of active pharmaceutical ingredients (APIs) and contract manufacturing of pharmaceutical products, primarily serving generic drug manufacturers.
Sector
Pharmaceuticals
Daito Pharmaceutical Co., Ltd. focuses on the manufacturing and sales of APIs and pharmaceutical products, as well as contract manufacturing and distribution, while also engaging in health food sales. In the API sector, the company manufactures and sells both in-house developed products and those co-developed with partners, maintaining extensive business relationships with domestic and international pharmaceutical companies. The company has a particularly strong track record in supplying APIs, mainly self-developed, to generic drug manufacturers. In pharmaceutical production, Daito actively engages in contract manufacturing of brand-name drugs for major domestic pharmaceutical companies, while also developing and manufacturing generic drugs. With its high-quality control capabilities and production facilities capable of handling various dosage forms, the company is able to undertake manufacturing contracts from major innovative drug companies. Daito's integrated manufacturing system, covering everything from APIs to finished pharmaceutical products, serves as a significant competitive advantage.